“Bill’s strong and significant senior executive leadership strengths will serve M Pharma in multiple ways, including financial analysis, acquisition and start-up activities, new market entry analysis, and strategic planning,” said Gary Thompson, president and chief executive.
Thompson added that the firm was looking forward to further additions to the board as it prepared to market the company’s strong portfolio of drugs and treatments within the obesity and women’s health space.
More recently Mr. Rodgers served as president and chief executive officer for EMCOR Facilities Services Inc. and GoodCents Holdings Inc.
M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity and weight management.
It has two potential blockbuster products: a side-effect-free version of the best-selling slimming product orlistat (probably better known to consumers as Xenical) and a female sexual dysfunction (FSD) remedy.
Add to that an infertility treatment and a handful of other revenue-generating products and you have a diversified healthcare business with significant blue-sky potential.
Story by ProactiveInvestors